Medical device company MC3 Cardiopulmonary reported on Thursday the availability of the US FDA approved Crescent Jugular Dual Lumen Catheter for ECMO (Extracorporeal membrane oxygenation) indication in patients with acute respiratory failure in the US.
The company added the Crescent catheter is placed through the jugular vein and is connected to an ECMO system, which removes carbon dioxide and reinfuses oxygenated blood.
According to the company, the Crescent Jugular Dual Lumen Catheter is a single use dual lumen catheter, which provides both venous drainage and re-infusion of blood via the jugular vein, that is indicated for use in patients with acute respiratory failure requiring Veno-Venous Extracorporeal Membrane Oxygenation. where other available treatment options have failed and continued clinical deterioration is expected or the risk of death is imminent.
Crescent's unique design permits unmatched flow performance, minimises re-circulation and enables smooth insertion, visible location and highly durable placement, concluded the company.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT